Obesity and Diabetes May Be Risk Factors for Recurrence of Hepatocellular Carcinoma, Study Reveals
A recent study has highlighted that the coexistence of obesity and Diabetes mellitus increased late recurrence and worsened prognosis in patients with Hepatocellular carcinoma undergoing hepatic resection. The findings were published in Liver Cancer.
Hepatocellular carcinoma is known to have a high recurrence rate after cancer removal. Recent advances in antiviral therapy have reduced the number of patients affected, but obesity and diabetes are factors in hepatocellular carcinoma prevalence. However, these factors’ effects on patient survival and cancer recurrence have been unclear.
To gain insights, Dr. Hiroji Shinkawa’s research team at Osaka Metropolitan University’s Graduate School of Medicine analyzed the relationship between diabetes mellitus, obesity, and postoperative outcomes in 1,644 patients with hepatocellular carcinoma who underwent liver resection.
The results revealed that the risk of recurrence after two years postoperatively was approximately 1.5 times higher in the case of comorbid obesity and 1.3 times higher in the case of diabetes mellitus. In addition, the risk of recurrence after five years postoperatively was 3.8 times higher in the case of comorbid obesity and 2 times higher in the case of comorbid diabetes alone.
“This study is expected to contribute to the early detection of cancer recurrence and the design of appropriate treatment strategies,” stated Dr. Shinkawa. “Because the risk of late recurrence is higher in hepatocellular carcinoma with comorbid obesity and diabetes, controlling obesity and diabetes is an important treatment strategy for hepatocellular carcinoma.”
Reference: Hiroji Shinkawa, Masaki Kaibori, Masaki Ueno, Satoshi Yasuda, Hisashi Ikoma, Tsukasa Aihara, Takuya Nakai, Masahiko Kinoshita, Hisashi Kosaka, Shinya Hayami, Yasuko Matsuo, Ryo Morimura, Takayoshi Nakajima, Chihoko Nobori, Takeaki Ishizawa; Impact of Diabetes Mellitus and Obesity Comorbidities on Survival Outcomes after Hepatocellular Carcinoma Resection: A Multicenter Retrospective Study. Liver Cancer 2024; https://doi.org/10.1159/000540858
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.